Aptyx Acquires Medical Murray’s North Carolina Facility to Expand Interventional Product Line
Tempe, AZ-based Aptyx, a global leader in developing and manufacturing complex components for the life sciences sector, has announced its acquisition of Medical Murray‘s Charlotte, North Carolina facility, known for its expertise in catheter-based interventional products and transcatheter implants. This strategic move marks the launch of Aptyx Interventional Systems and signifies a significant expansion in Aptyx’s service offerings and manufacturing capabilities.
The Charlotte team will be integrated into Aptyx, while Medical Murray will continue its operations at its remaining facilities in the Chicagoland area. The newly acquired facility will operate under Aptyx Interventional Systems, bolstering the company’s portfolio with advanced manufacturing capabilities and specialized expertise in catheter-based products and transcatheter solutions like implantable stents and frames. This expansion not only enlarges Aptyx’s ISO Class 7 footprint but also brings in a wealth of engineering talent and expertise in biotextiles such as ePTFE coverings for stents.
Gregg Tobin, President and CEO of Aptyx, stated, “This acquisition is a pivotal part of our growth strategy. It enhances our end-to-end solutions, driving innovation and delivering enhanced value to our OEM customers. This integration is just the beginning of our planned expansions and innovations.”
Eric Leopold, former CTO of Medical Murray and leader of the Charlotte business, will join Aptyx as Senior Vice President. He commented, “This merger fuels our long-term growth and enhances our ability to tackle technical challenges across vital markets like structural heart and neurovascular sectors efficiently.”
John Pless, Co-Managing Partner at TruArc, emphasized the strategic importance of this acquisition: “The inclusion of Aptyx Interventional Systems not only strengthens our presence in the interventional market but also complements our high-value manufacturing and development capabilities, solidifying our position as a leading manufacturing partner in the life sciences industry.”
